Latest Trials Latest NewsFAQ

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

Phase 2

Completed

Conditions: Hot Flashes
Menopause
Night Waking

Interventions: Drug: Elinzanetant (BAY3427080)
Drug: Placebo

First Posted Date: 2018-07-24

Last Posted Date: 2023-03-10

Lead Sponsor: Bayer

Target Recruit Count: 199

Registration Number: NCT03596762

Locations: 🇺🇸
Study Site 13, Aventura, Florida, United States
🇺🇸
Study Site 15, Lake Worth, Florida, United States
🇨🇦
Study Site 50, Red Deer, Alberta, Canada

and more 22 locations

Study of BAY1834942 in Patients With Solid Tumors

Phase 1

Completed

Conditions: Advanced CEACAM6-expressing Solid Tumors

Interventions: Drug: BAY1834942

First Posted Date: 2018-07-23

Last Posted Date: 2022-06-02

Lead Sponsor: Bayer

Target Recruit Count: 30

Registration Number: NCT03596372

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇨🇦
Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada

and more 1 locations

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

Phase 1

Active, not recruiting

Conditions: Hemophilia A

Interventions: Drug: BAY2599023 (DTX201)

First Posted Date: 2018-07-17

Last Posted Date: 2024-12-16

Lead Sponsor: Bayer

Target Recruit Count: 11

Registration Number: NCT03588299

Locations: 🇧🇬
SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia, Bulgaria
🇺🇸
University of Wisconsin - Madison, Madison, Wisconsin, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 10 locations

EffectiveNess of Low Dose Aspirin in GastrointEstinal Cancer Prevention - Taiwan

Completed

Conditions: Colorectal Neoplasms

Interventions: Other: No drug
Drug: Aspirin (Acetylsalicylic Acid, BAYE4465)

First Posted Date: 2018-07-09

Last Posted Date: 2020-09-29

Lead Sponsor: Bayer

Target Recruit Count: 4710504

Registration Number: NCT03579732

Locations: 🇨🇳
National University of Taiwan Hospital, Taipeh, Taiwan

Betaferon Use in Children and Adolescents With Multiple Sclerosis

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)

First Posted Date: 2018-07-05

Last Posted Date: 2018-07-11

Lead Sponsor: Bayer

Target Recruit Count: 70

Registration Number: NCT03577977

Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis

Phase 2

Terminated

Conditions: Endometriosis

Interventions: Drug: Vilaprisan (BAY1002670)
Drug: Matching Placebo

First Posted Date: 2018-06-29

Last Posted Date: 2022-05-04

Lead Sponsor: Bayer

Target Recruit Count: 8

Registration Number: NCT03573336

Locations: 🇦🇹
Medizinische Universität Graz, Graz, Steiermark, Austria
🇦🇹
KABEG Landeskrankenhaus Villach, Villach, Austria
🇺🇸
Unified Women's Clinical Research, Winston-Salem, North Carolina, United States

and more 20 locations

A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale

Phase 2

Completed

Conditions: Osteoarthritis, Knee

Interventions: Drug: Naproxen Sodium (Aleve, BAY117031)
Drug: Acetaminophen ER
Drug: Celecoxib
Drug: Placebo

First Posted Date: 2018-06-27

Last Posted Date: 2020-06-19

Lead Sponsor: Bayer

Target Recruit Count: 41

Registration Number: NCT03570554

Locations: 🇺🇸
Radiant Research, Inc., San Antonio, Texas, United States

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

Phase 4

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2018-06-21

Last Posted Date: 2024-12-03

Lead Sponsor: Bayer

Target Recruit Count: 100

Registration Number: NCT03564938

Locations: 🇮🇳
Apollo Research Foundation, Hyderabad, Andhra Pradesh, India
🇮🇳
Sir Ganga Ram Hospital, New-Delhi, Delhi, India
🇮🇳
Shalby Hospital, Ahmedabad, Gujarat, India

and more 10 locations

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Phenprocoumon
Drug: Apixaban
Drug: Edoxaban

First Posted Date: 2018-06-20

Last Posted Date: 2020-11-27

Lead Sponsor: Bayer

Target Recruit Count: 64920

Registration Number: NCT03563937

Locations: 🇩🇪
Many Locations, Multiple Locations, Germany

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223

Completed

Conditions: Prostatic Neoplasms, Castration-Resistant

Interventions: Drug: Radium-223 (Xofigo, Bay88-8223)

First Posted Date: 2018-06-20

Last Posted Date: 2020-05-20

Lead Sponsor: Bayer

Target Recruit Count: 164

Registration Number: NCT03563014

Locations: 🇧🇪
Many Locations, Multiple Locations, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy